Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416857 | 0.87 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL19347052 | 0.86 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL16417092 | 0.84 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL30035566 | 0.83 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL19332152 | 0.83 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL19332051 | 0.81 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL30035540 | 0.81 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL19332066 | 0.81 | SMN1; SMN2 (0.47) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL18407966 | 0.79 | BACE1 (0.56) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL16416881 | 0.79 | MAOB (0.44) | RAB9ANPC1SMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | EMORY UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| CN-109153640-B | Eliminating hepatitis B virus with antiviral agent | 埃默里大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-04-22 | — | — | US | disclosed |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-04-22 | — | — | US | disclosed |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | EMORY UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | EMORY UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3426633-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | Emory University (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017156255-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156255-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.